Shiratsuchi K, Fuse H, Hagiwara M, Mikami T, Miyasaka K, Sakuma H
Pharmacological Research Department, Teikoku Hormone Mfg. Co., Ltd., Kawasaki, Japan.
Arch Int Pharmacodyn Ther. 1988 Jul-Aug;294:295-304.
The cytoprotective action of roxatidine acetate HCl (roxatidine) was investigated. We also studied the involvement of endogenous prostaglandins (PGs) in the cytoprotective action of roxatidine and the effect of roxatidine on SRS content in pleurisy induced by A23187. Simultaneously, these effects of roxatidine were compared with those of other histamine H2-receptor antagonists at the same anti-secretory activity level. Roxatidine prevented formation of the gastric mucosal lesions induced by abs. ethanol, 0.6 N HCl and 0.2 N NaOH, but it failed to prevent 30% NaCl-induced gastric mucosal lesions. Cimetidine, ranitidine and famotidine failed to prevent formation of the gastric mucosal lesions induced by necrotizing agents. The cytoprotective action of roxatidine was not abolished by pretreatment with indomethacin. Roxatidine did not greatly influence SRS production. Consequently, it appears that roxatidine has a cytoprotective action and that this action is not associated with endogenous PGs and SRS.
研究了盐酸罗沙替丁（罗沙替丁）的细胞保护作用。我们还研究了内源性前列腺素（PGs）在罗沙替丁细胞保护作用中的参与情况以及罗沙替丁对A23187诱导的胸膜炎中SRS含量的影响。同时，在相同的抗分泌活性水平下，将罗沙替丁的这些作用与其他组胺H2受体拮抗剂的作用进行了比较。罗沙替丁可预防无水乙醇、0.6N盐酸和0.2N氢氧化钠诱导的胃黏膜损伤，但不能预防30%氯化钠诱导的胃黏膜损伤。西咪替丁、雷尼替丁和法莫替丁不能预防坏死剂诱导的胃黏膜损伤。吲哚美辛预处理不能消除罗沙替丁的细胞保护作用。罗沙替丁对SRS的产生影响不大。因此，罗沙替丁似乎具有细胞保护作用，且该作用与内源性PGs和SRS无关。
